Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL Therapy for Metastatic Ovarian Cancer
NCT02482090Phase 1Completed
- Start
- Jul 2015
- Primary completion
- Dec 2016
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of therapeutic tumor-infiltrating lymphocytes in Malignant ovarian neoplasm (OC). Primary endpoint: Adverse Events at 24 weeks. Started Jul 2015; status: completed.
02
Drugs
therapeutic tumor-infiltrating lymphocytes
03
Conditions
Malignant ovarian neoplasm (OC)
Beyond the preview
Go deeper on NCT02482090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02482090.